Evidence map›Paper›PMID 37256503›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

Greater Combined Reductions of HbA

Kathleen M Dungan, Lars Bardtrum, Erik Christiansen, Johanna Eliasson, Linda Mellbin, Vincent C Woo, Tina Vilsbøll

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Kathleen M DunganDivision of Endocrinology, Diabetes and Metabolism, The Ohio State University, 1581 Dodd Drive, Columbus, OH 43210, USA. kathleen.dungan@osumc.edu.ORCID http://orcid.org/0000-0003-1289-1595
Lars BardtrumNovo Nordisk A/S, Søborg, Denmark.
Erik ChristiansenNovo Nordisk A/S, Søborg, Denmark.
Johanna EliassonNovo Nordisk A/S, Søborg, Denmark.
Linda MellbinDepartment of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
Vincent C WooSection of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, Canada.
Tina VilsbøllClinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
Novo Nordisk (Denmark) · DKKarolinska Institutet · SEThe Ohio State University · USUniversity of Copenhagen · DKUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA post hoc analysis of the PIONEER 1-5 and 8 trials assessed the clinically relevant composite endpoints of HbA

methodsIn the PIONEER trials, people with type 2 diabetes were randomised to orally administered semaglutide versus placebo (PIONEER 1, 4, 5 and 8), empagliflozin (PIONEER 2), sitagliptin (PIONEER 3) and liraglutide (PIONEER 4) for 26-78 weeks. This analysis assessed the proportion of people achieving an HbA

resultsOverall, 3506 people in PIONEER 1-5 and 8 were included. At week 26 and at end of treatment, odds of achieving the composite endpoint of an HbA

conclusionIn PIONEER 1-5 and 8, odds of achieving clinically relevant reductions in both HbA

Indexed as

Body weight lossComposite endpointGlucagon-like peptide 1 analogueGlycaemic controlType 2 diabetes

Identifiers

PMID37256503
PMCPMC10299987
OpenAlexW4378783299

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.